---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-294108"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T17:12:45.009582+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Aptose Biosciences to be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash

## Summary
- Hanmi subsidiary will acquire all outstanding Aptose shares at C$2.41 each, a 28% premium over the 30-day VWAP of C$1.88 on TSX.
- Aptose board unanimously recommends the arrangement after unanimous recommendation from a special committee of independent directors.
- Transaction requires approval by two-thirds of votes cast and minority approval excluding Hanmi affiliates; special meeting by Jan 16, 2026.
- Non-solicitation provisions with a C$300,000 expense fee payable to Hanmi if agreement terminated under certain conditions.
- Post-closing, Aptose shares will be delisted from TSX and the company will cease reporting under Canadian securities legislation.

## SEC filing metadata
- accession: 0001193125-25-294108
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000119312525294108/0001193125-25-294108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000119312525294108/d25723d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-294108
- JSON: https://secwatch.observer/filing/0001193125-25-294108.json
- Plain text: https://secwatch.observer/filing/0001193125-25-294108.txt

## Key facts
- Material Agreements
  Aptose Biosciences Inc. entered into Arrangement Agreement with Hanmi Pharmaceuticals Co. Ltd. and HS North America Ltd. valued at C$2.41 in cash per Common Share (effective 2025-11-18).
  - Action: entry
  - Agreement: merger
  - Counterparty: Hanmi Pharmaceuticals Co. Ltd. and HS North America Ltd.
  - Value: C$2.41 in cash per Common Share
  - Effective: 2025-11-18
  source text: On November 18, 2025, Aptose Biosciences Inc. (the “ Company ”), Hanmi Pharmaceuticals Co. Ltd. (“ Hanmi ”) and HS North America Ltd., a wholly owned subsidiary of Hanmi (“ Hanmi Purchaser ” and together with Hanmi, the “ Hanmi Purchasers ”), entered into a definitive arrangement agreement (the “ Arrangement Agreement ”) pursuant to which Hanmi Purchaser will acquire all of the issued and outstanding common shares of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000119312525294108/0001193125-25-294108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.